期刊文献+

高通量透析对维持性血液透析患者慢性并发症的影响 被引量:8

Effect of high-flux hemodialysis on chronic complications in patients with maintenance hemodialysis
下载PDF
导出
摘要 目的探讨高通量透析对维持性血液透析患者慢性并发症的影响。方法自身对照研究35例稳定的维持性血液透析患者由低通量透析改为高通量透析1年时的临床资料,观察并比较Hb、血清白蛋白、超敏C反应蛋白、血磷、甲状旁腺激素水平,血压、降压药物使用种类变化。结果改高通量透析1年后患者Hb水平由(92.4±12.5)g/L升至(111.6±11.2)g/L(P<0.05),血清白蛋白由(36.1±2.5)g/L升至(39.5±2.8)g/L(P<0.05),超敏C反应蛋白由(8.51±1.42)mg/L降至(6.31±2.11)mg/L(P<0.05),血磷由(2.18±0.36)mmol/L下降到(1.72±0.32)mmol/L(P<0.05),甲状旁腺激素由(420.5±130.1)pg/ml下降到(210.5±108.2)pg/ml(P<0.05),透析前收缩压由原来(155.8±10.4)mmHg降为(140.3±10.2)mmHg(P<0.05),舒张压由原来(92.8±6.9)mmHg降为(83.2±4.2)mmHg(P<0.05),使用降压药种类由(3.3±1.2)种降为(1.8±1.4)种(P<0.05)。结论高通量透析较低通量透析可以更好地纠正透析患者肾性贫血、改善其营养状况、微炎症状态、增加磷、甲状旁腺激素清除,对顽固性高血压有较好控制作用,从而减少长期透析所致的各种并发症,提高患者生存质量及存活率。 Objective To investigate the effects of high-flux hemodialysis on chronic complications in patients with maintenance hemodialysis. Methods Thirty five patients with maintenance hemodialysis changed from low flux dialysis to high flux dialysis. One year after the dialysis mode change, the hemoglobin, serum albumin, hypersensitive C-reactive protein (hs-CRP) and blood phosphorus, parathyroid hormone levels, blood pressure, types of antihypertensive drugs use were documented and compared with those before change. Results One year after dialysis mode change, the hemoglobin levels were increased from (92.4 ± 12.5) g/L to (111.6 ± 11.2) g/L, serum albumin from (36.1 ± 2.5) g/L to (39.5 ± 2.8 )g/L, hs-CRP levels were decreased from(8.51± 1.42) mg/L to(6.31 ± 2.11)/mg/L, blood phosphorus from (2.18 ± 0.36) mmol/L fell to (1.72 ± 0.32) mmol/L, parathyroid hormone from (420.5 ± 130.1) pg/ml to (210.5 ± 108.2) pg/ml; the systolic blood pressure decrease from (155.8 ± 10.4) mmHg to ( 140.3 ± 10.2 )mmHg, diastolic blood pressure from (92.8 ± 6.9) mmHg to (83.2±4.2)mmHg, the types of antihypertensive drugs from (3.3 ± 1.2) to (1.8 ± 1.4) (all P〈0.05). Conclusion High-flux hemodialysis can reduce or improve the chronic complications in patients with long-term maintenance hemodialysis.
出处 《浙江医学》 CAS 2015年第19期1585-1587,1603,共4页 Zhejiang Medical Journal
关键词 维持性血液透析 高通量透析 慢性并发症 Maintenance hemodialysis High-flux hemodialysis Chronic complications
  • 相关文献

参考文献13

  • 1Waikar S S, Curhan G C, Brunelli S M. Mortality associated with low serum sodium concentration in maintenance hemodialysis[J]. TheAmerican Journal of Medicine, 2011, 124(1 ):77 - 84.
  • 2李月红,王梅.北京市2007年慢性维持性血液透析患者钙磷代谢分析[J].中国血液净化,2010,9(2):112-115. 被引量:56
  • 3Yoshino M, Kuhlmann M K, Kotanko P, et al. International differ- ences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality[J]. J Am Soc Nephrol, 2006, 17(12): 3510-3519.
  • 4王质刚.超纯透析液及其临床意义[J].中国血液净化,2009,8(8):407-409. 被引量:5
  • 5殷培,李冀军,宋岩,王建红,陈凤锟,赵长征.高通量血液透析对血清铁调素水平变化的影响及相关因素分析[J].中国血液净化,2014,13(1):8-11. 被引量:10
  • 6Zaritsky J, Young B, Wang H J, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease[J]. Clin J Am Soc Nephrol,2009,4(6): 1051-1056.
  • 7王逸申,汪年松.维持性血液透析患者贫血机制的研究进展[J].中国中西医结合肾病杂志,2011,12(8):738-741. 被引量:23
  • 8Slatopolsky E, Moe S. 50 years of research and discovery in chronic kidney disease and mineral and bone disorder:the centralrole of phosphate[J].Kidney Int Suppl,2011,121:1-2.
  • 9Kong X,Zhang L, Zhang L,et aI.Mineral and bone disorder in Chi- nese Dialysis patients: a multicenter study[J]. BMC Nephrol,2012, 13:116.
  • 10Palmer S C, Hayen A, Macaskill P, et al. Serum Levels of phos- phorus, Parathyroid hormone,and calcium and risks of death and cardiovascular disease in individuals with chronic Kidney disease: a systematic review and meta-analysis[J]. JAMA,2011, 305(11):1119-1127.

二级参考文献99

  • 1卢永申,阮励冰,赵显国.应用超纯透析液降低血液透析患者血浆C反应蛋白水平[J].中国血液净化,2004,3(7):406-406. 被引量:8
  • 2闭闵,李家燕,肖华秀,龚智峰,吴潮清,王浩宇.超纯水对维持性血液透析患者营养不良及贫血的影响[J].广西医学,2004,26(9):1267-1269. 被引量:10
  • 3Ingrid Ledebo. Ultrapure dialysis fluid-direct and indi- rect benefits in dialysis therapy[J]. Blood Purif, 2004, 22(suppl 2):20-25.
  • 4Arizono K, Nomura K, Motoyama T, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis[J]. Blood Purif, 2004,22 Suppl 2:26-29.
  • 5Guth HJ, Gruska S, Kraatz G. On-line production of ultrapure substitution fluid reduces TNF-alpha- and IL-6 release in patients on hemodiafiltration therapy[J]. Int J Artif Organs, 2003,26:181-187.
  • 6Izuhara Y, Miyata T, Saito K, et al. Ultrapure dialysate decreases plasma pentosidine, a marker of "carbonyl stress" [J]. hm J Kidney Dis, 2004,43:1024-1029.
  • 7Ryuichi Furuya, Hiromichi, Kumagai, et al. Ultrapure Dialysate Reduces Plasma Levels of β 2-Microglobulin and Pentosidine in Hemodialysis Patients[J]. Blood Purif, 2005, 23:311-316.
  • 8Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflamation[J]. Nephron, 2002,91:452-455.
  • 9Bernard Canaud, Katja Martin, Marion Morena. Monitoring the microbial purity of the treated water and dialysate [J]. Saudi J Kidney Dis Transpl, 2001, 12:325-326.
  • 10Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study [J]. J Nephrol, 2004,17: 693-700.

共引文献113

同被引文献76

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部